75
Participants
Start Date
July 5, 2016
Primary Completion Date
July 10, 2017
Study Completion Date
July 10, 2017
Placebo
Matching-placebo capsules will be administered orally, 2 times a day with food.
RO5459072
RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
Charité Research Organisation GmbH, Berlin
Winthrop University Hospital, Mineola
University of Pittsburgh Medical Center, Pittsburgh
Altoona Center For Clinical Research, Duncansville
Clinical Research Center of Reading, Wyomissing
John Hopkins Bayview Medical Center, Baltimore
Shanahan Rheumatology & Immunology, PLLC, Raleigh
Hopital La Cavale Blanche; Rhumatologie, Brest
Hopital Lapeyronie; Immunologie Rhumatologie, Montpellier
Ramesh Gupta - PP, Memphis
MetroHealth System, Cleveland
University Of Michigan, Ann Arbor
Ochsner Clinic Foundation, Baton Rouge
Wallace Rheumatic Study Center, Beverly Hills
C.H.U. Ambroise Pare (AP-HP), Boulogne-Billancourt
Hopital Avicenne, Paris, Bobigny
Denver Arthritis Clinic, Denver
Szpital Uniwersytecki; nr 2 im. Dr J. Biziela; Klinika Reumatologii i Ukladowych Chorob, Bydgoszcz
MedPolonia, Poznan
Niepubliczny Opieki Zdrowotnej; Reumatika - Ctr Reum., Warsaw
Centrum Medyczne AMED, Warsaw
Instituto Portugues de Reumatologia, Lisbon
Centro Hospitalar de Lisboa Norte, EPE - Hospital Santa Maria, Lisbon
Centro Hospitalar do Porto - Hospital de Santo António, Porto
Centro Hospitalar de Sao Joao,E.P.E., Porto
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Barts and the London NHS Trust, London
University College London Hospitals NHS Foundation Trust - University College Hospital, London
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Sheffield Teaching Hospitals NHS Foundation Trust; Royal Hallamshire Hospital, Sheffield
Great Western Hospitals NHS Foundation Trust., Wiltshire
Hoffmann-La Roche
INDUSTRY